← Back to Search

Relugolix + Radiation Therapy for Prostate Cancer

Phase 2
Waitlist Available
Led By Xinglei Shen
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1
Must not have
Current or anticipating use of other anti-neoplastic or investigational agents while participating in this study
Prior prostatectomy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial will investigate the best duration of relugolix + radiation to treat high risk prostate cancer, to see if it's more effective and has fewer side effects than current hormone therapy.

Who is the study for?
This trial is for men over 18 with high risk prostate cancer who can consent to the study, have a life expectancy over 5 years, and are eligible for radiation therapy combined with ADT. They must have good organ function and agree to use contraception. It's not for those in other clinical trials, using anti-cancer drugs, with severe infections or psychiatric/social limitations, allergic reactions to study drug components, current ADT (unless testosterone levels are adequate), or prior treatments that overlap with this study.
What is being tested?
The trial is testing how long relugolix should be given alongside standard radiation therapy in treating high-risk prostate cancer. Relugolix lowers testosterone which may help slow down the growth of prostate cancer cells. The goal is to find out if adding relugolix improves outcomes and has fewer side effects than previous hormonal therapies.
What are the potential side effects?
Relugolix may cause hot flashes, fatigue, diarrhea, joint pain and changes in liver function tests. Since it lowers testosterone levels significantly, it might also lead to decreased sex drive or erectile dysfunction.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I am fully active or can carry out light work.
Select...
My prostate cancer is classified as high or very high risk.
Select...
I am eligible for a specific cancer treatment involving radiation and hormone therapy.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not using, nor plan to use, other cancer treatments during this study.
Select...
I have had surgery to remove my prostate.
Select...
I haven't had a severe infection in the last 2 weeks.
Select...
I have had previous treatments in my pelvic area that overlap with where I would receive radiation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Biochemical recurrence
Secondary study objectives
Composite quality of Life
Incidence of adverse events
Incidence of major adverse cardiovascular events
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm B (relugolix, brachytherapy, external beam radiation)Experimental Treatment10 Interventions
Patients receive relugolix PO QD. Cycles repeat every 3 months for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 30 to 180 days after start of relugolix, patients undergo brachytherapy and external beam radiation over 25 fractions. Patients undergo bone scan, CT or MRI or PSMA PET scan during screening. Patients also undergo DEXA scan and may optionally undergo blood sample collection throughout the trial.
Group II: Arm A (relugolix, brachytherapy, external beam radiation)Experimental Treatment10 Interventions
Patients receive relugolix PO QD. Cycles repeat every 3 months for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 30 to 180 days after start of relugolix, patients undergo brachytherapy and external beam radiation over 25 fractions. Patients undergo bone scan, CT or MRI or PSMA PET scan during screening. Patients also undergo DEXA scan and may optionally undergo blood sample collection throughout the trial.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dual X-ray Absorptiometry
2015
N/A
~50
Bone Scan
2015
Completed Phase 2
~50
Biospecimen Collection
2004
Completed Phase 3
~2020
Brachytherapy
2007
Completed Phase 3
~2130
Magnetic Resonance Imaging
2017
Completed Phase 3
~1160
Relugolix
2016
Completed Phase 3
~5360
Computed Tomography
2017
Completed Phase 2
~2740
External Beam Radiation Therapy
2006
Completed Phase 3
~3300
PSMA PET Scan
2020
N/A
~10

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,842 Previous Clinical Trials
41,002,910 Total Patients Enrolled
567 Trials studying Prostate Cancer
529,809 Patients Enrolled for Prostate Cancer
University of Kansas Medical CenterLead Sponsor
488 Previous Clinical Trials
172,365 Total Patients Enrolled
11 Trials studying Prostate Cancer
489 Patients Enrolled for Prostate Cancer
Xinglei ShenPrincipal InvestigatorUniversity of Kansas
~51 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top